Eye Catching Stock News: Akebia Therapeutics, Inc. (NASDAQ: AKBA)

On 08 May 2020, Akebia Therapeutics, Inc. (NASDAQ: AKBA) changed 2.57% to recent value of $11.98. The stock transacted 2060753 shares during most recent day however it has an average volume of 1644.42K shares. It spotted trading -2.20% off 52-week high price. On the other end, the stock has been noted 300.67% away from the low price over the last 52-weeks.

Akebia Therapeutics, Inc. (AKBA) recently reported financial results for the fourth quarter and full-year ended December 31, 2019.

Fourth Quarter and Full-Year 2019 Financial Results

  • Cash Position: Cash, cash equivalents and available-for-sale securities as of December 31, 2019 were $147.7M.
  • Revenues:Total revenue was $69.6M for the fourth quarter of 2019 contrast to $59.9M for the fourth quarter of 2018(1), and $335.0M for the full-year 2019 contrast to $207.7M for the full-year 2018(1).
    • Alliance revenue was $40.6M for the fourth quarter of 2019 contrast to $53.0M in the fourth quarter of 2018, and $223.9M for the full-year 2019 contrast with $200.9M for the full-year 2018. The change in both periods is Because of the timing in which vadadustat development expenses are incurred and the associated revenue is recognized on a percentage-of-completion basis.
    • Net product revenue was $28.9M for the fourth quarter of 2019 contrast with $6.8M in the fourth quarter of 2018(1), and $111.1M for the full-year 2019 contrast to $6.8M for the full-year 2018(1). Pro forma net product revenue for the full-year 2018, inclusive of pre-merger net product revenue recorded by Keryx Biopharmaceuticals, Inc. (Keryx), was about $96M.
  • COGS: Cost of goods sold was $38.1M for the fourth quarter of 2019, which includes non-cash charges, related to the application of purchase accounting as a result of the merger with Keryx, of $18.8M for inventory step-up and $9.1M for amortization of intangibles.Cost of goods sold was $145.3M for the full-year 2019, which includes non-cash charges of $70.4M for inventory step-up and $36.4M for amortization of intangibles.
  • R&D Expenses:Research and development expenses were $80.4M for the fourth quarter of 2019 contrast to $87.1M for the fourth quarter of 2018(1), and $323.0M for the full-year 2019 contrast to $291.0M for the full-year 2018(1).The change in both periods was largely attributable to a change in costs associated with our research and development programs, including vadadustat.
  • SG&A Expenses:Selling, general and administrative expenses were $44.9M for the fourth quarter of 2019 contrast to $55.1M for the fourth quarter of 2018(1) (which included $41.7M of merger-related expenses), and $149.5M for the full-year 2019 contrast to $87.1M for the full-year 2018(1) (which included $49.5M of merger-related expenses).
  • Net Loss:Net loss was $94.5M for the fourth quarter of 2019 contrast to $60.1M for the fourth quarter of 2018(1), and $279.7M for the full-year 2019 contrast to $143.6M for the full-year 2018(1).

AKBA has a gross margin of 66.40% and an operating margin of -85.40% while its profit margin remained -83.50% for the last 12 months. Its earnings per share (EPS) expected to touch remained 4.50% for this year. The company has 132.23M of outstanding shares and 125.49M shares were floated in the market. According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 45.45% from the mean of 20 days, 57.54% from mean of 50 days SMA and performed 99.70% from mean of 200 days price. Company’s performance for the week was 50.13%, 72.37% for month and YTD performance remained 89.56%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *